The consensus statement recommends GLP-1/GIP therapy for: Adults with T1D who have overweight or obesity (BMI of 30 or higher, or 27 or higher with other health conditions) Adults with T1D who arent hitting their blood sugar goals with insulin alone, even at a healthy weight Teens and young adults with T1D who have overweight or obesity and arent reaching their targets on insulin or who are meeting targets but might still benefit If your BMI drops below 25, or was 25 or under when treatment started, your healthcare provider should check in regularly and may pause or stop the medication altogether
This suggests that this peptide has a positive impact on the heart, especially in clot-related conditions [4]
Additionally, the TRAF1-C5 gene, an immune-related gene, functions in the initiation and progression of inflammation, offering predictive value for assessing the severity of RA, particularly concerning joint destruction [28]
Acceptable evidence includes any dated document or image issued within the past 30 dayssuch as a pharmacy dispensing label, electronic health-record screenshot, insurance explanation of benefits, clinical-trial visit summary, medication package showing a pharmacy sticker, refill receipt, or telehealth prescriptionprovided it clearly references a GLP-1 product (examples include semaglutide, liraglutide, dulaglutide, exenatide, lixisenatide, tirzepatide, or their brand or generic names)
Most Charlotte patients prefer sticking to a routine and selecting a consistent weekday for their injections
While this approach limits exploration to modifications around established peptide scaffolds, it provides a rational framework for systematic optimization that may identify therapeutically relevant improvements within well-characterized chemical space
